TLSI

TriSalus Life Sciences, Inc. (TLSI) Management Analysis (2026)

Invetso Score: 2.8/10 — Weak · Last Updated: 2026-08-01

Overall Score

Leadership Execution

Management is operating with very weak profitability, with TTM net margin at -62.6% and operating margin at -67.7%.

Execution is further pressured by negative TTM operating cash flow and free cash flow, indicating the business is not self-funding.

The balance sheet remains liquid with a current ratio of 5.35 and cash ratio of 4.14, but this does not offset the poor operating performance.

Capital Allocation

Capital allocation appears constrained by persistent losses and negative free cash flow, limiting flexibility for reinvestment or shareholder returns.

Leverage is elevated, with debt-to-equity at 5.26 and debt-to-capital at 0.84, which raises the cost of missteps.

There is no dividend support from the current TTM data, and the company is not generating positive cash returns to fund buybacks or deleveraging.

Incentives Governance

The available financial data does not provide direct evidence of incentive alignment or governance quality.

However, the combination of negative returns on capital and high leverage suggests governance is not yet translating into durable value creation.

No material governance-related news was reported this month.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on TriSalus Life Sciences, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →